| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
289,870,000 |
| Market
Cap: |
67.58(B) |
| Last
Volume: |
891,669 |
Avg
Vol: |
1,407,320 |
| 52
Week Range: |
$232.24 - $283.59 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 224 |
| Guru Rank Value : 5.4 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Becton, Dickinson and Company is a medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. Co.'s business segments are: BD Medical, which produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings; BD Life Sciences, which provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers; and BD Interventional, which provides vascular, urology, oncology and surgical products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
282 |
3,677 |
9,258 |
39,261 |
| Total Sell Value |
$67,198 |
$869,357 |
$2,420,786 |
$10,261,828 |
| Total People Sold |
1 |
3 |
5 |
7 |
| Total Sell Transactions |
1 |
3 |
7 |
14 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ezell Antoine C |
EVP, President NA & CMO |
• – – |
2023-11-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,069 |
11,256 |
|
- |
|
| Goette Roland |
EVP and President EMEA |
• – – |
2023-11-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(213) |
18,390 |
|
- |
|
| Goette Roland |
EVP and President EMEA |
• – – |
2023-11-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,190 |
18,603 |
|
- |
|
| Delorefice Christopher |
EVP & Chief Financial Officer |
• – – |
2023-11-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(812) |
13,512 |
|
- |
|
| Delorefice Christopher |
EVP & Chief Financial Officer |
• – – |
2023-11-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,325 |
14,324 |
|
- |
|
| Garrison Michael David |
EVP & President Medical |
• – – |
2023-11-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,646) |
8,513 |
|
- |
|
| Garrison Michael David |
EVP & President Medical |
• – – |
2023-11-26 |
4 |
A |
$0.00 |
$0 |
D/D |
5,002 |
10,159 |
|
- |
|
| Mocherla Pavan Kumar |
EVP & President Greater Asia |
• – – |
2023-11-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(64) |
1,817 |
|
- |
|
| Mocherla Pavan Kumar |
EVP & President Greater Asia |
• – – |
2023-11-26 |
4 |
A |
$0.00 |
$0 |
D/D |
751 |
1,881 |
|
- |
|
| Spoerel Thomas J |
SVPController & Chief Acct Off |
• – – |
2023-11-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(365) |
2,594 |
|
- |
|
| Spoerel Thomas J |
SVPController & Chief Acct Off |
• – – |
2023-11-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,132 |
2,959 |
|
- |
|
| Byrd Richard |
EVP & President Interventional |
• – – |
2023-11-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,509) |
6,276 |
|
- |
|
| Byrd Richard |
EVP & President Interventional |
• – – |
2023-11-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,341 |
7,785 |
|
- |
|
| Hickey David |
EVP & President, Life Sciences |
• – – |
2023-11-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,663 |
5,862 |
|
- |
|
| Goette Roland |
EVP and President, EMEA |
• – – |
2023-11-16 |
4/A |
D |
$235.07 |
$524,911 |
D/D |
(2,233) |
14,931 |
|
- |
|
| Goette Roland |
EVP and President, EMEA |
• – – |
2023-11-16 |
4 |
D |
$235.07 |
$411,608 |
D/D |
(1,751) |
15,413 |
|
- |
|
| Goette Roland |
EVP and President, EMEA |
• – – |
2023-11-16 |
4 |
OE |
$107.12 |
$379,633 |
D/D |
3,544 |
17,164 |
|
- |
|
| Delorefice Christopher |
EVP & Chief Financial Officer |
• – – |
2023-09-07 |
4 |
D |
$0.00 |
$0 |
D/D |
(601) |
10,999 |
|
- |
|
| Byrd Richard |
EVP & President Interventional |
• – – |
2023-09-05 |
4 |
S |
$274.48 |
$125,986 |
D/D |
(459) |
3,444 |
|
13% |
|
| Delorefice Christopher |
EVP & Chief Financial Officer |
• – – |
2023-09-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(353) |
11,600 |
|
- |
|
| Byrd Richard |
EVP & President Interventional |
• – – |
2023-09-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(216) |
3,903 |
|
- |
|
| Fraser-Liggett Claire |
Director |
– • – |
2023-08-28 |
4 |
S |
$281.66 |
$238,848 |
D/D |
(848) |
21,608 |
|
14% |
|
| Hickey David |
EVP & President, Life Sciences |
• – – |
2023-08-11 |
4 |
S |
$277.85 |
$826,326 |
D/D |
(2,974) |
4,199 |
|
15% |
|
| Hickey David |
EVP & President, Life Sciences |
• – – |
2023-08-11 |
4 |
D |
$277.85 |
$515,967 |
D/D |
(1,857) |
7,173 |
|
- |
|
| Hickey David |
EVP & President, Life Sciences |
• – – |
2023-08-11 |
4 |
OE |
$132.54 |
$514,653 |
D/D |
3,883 |
9,030 |
|
- |
|
1851 Records found
|
|
Page 2 of 75 |
|
|
2.14 (0.93%) 
